Lundbeck ready to take Genmab antibody to phase II

11 years after having entered into a partnership with Genmab about the antibody treatment for disease in the central nervous system, Lundbeck is now ready to start a phase II trial with a potential treatment for multiple system atrophy (MSA).

After an 11-year collaboration, the Danish alliance between Genmab and Lundbeck has reached another clinical milestone, according to the database Clinical Trials, which collects information about research studies.

Lundbeck is slated to test its candidate Lu AF82422 in patients with multiple system atrophy (MSA), which is a neurodegenerative disorder related to Parkinson's disease, which is why the disease is also described as an atypical parkinsonism.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs